| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Patient revenue, net | $72K | — | — | $14.4M+12.1% | $12.8M |
| Cost of revenues | $305K | — | — | — | — |
| Gross profit (loss) | -$233K | — | — | — | — |
| General and administrative | $5.4M+83.2% | $2.9M+19.3% | $2.5M-61.6% | $6.4M+41.0% | $4.6M |
| Loss on disposition or impairment | $3.4M | — | $4.5M+2919.6% | $149K+134.3% | $64K |
| Total operating expenses | $5.4M-15.5% | $6.4M-46.1% | $11.8M-51.7% | $24.5M+26.4% | $19.4M |
| Operating loss | -$5.6M+11.8% | -$6.4M+46.1% | -$11.8M-17.2% | -$10.1M-54.5% | -$6.5M |
| Interest income | $3K-87.2% | $27K+176.0% | $10K+241.0% | $3K-52.5% | $6K |
| Other income (expense) | -$2K | — | -$574-101.0% | $57K | — |
| Interest expense | -$678K-442.5% | -$125K-3864.7% | -$3K+99.4% | -$504K+10.5% | -$563K |
| Total other income (expenses) | -$675K-575.5% | -$100K-1733.4% | $6K+101.4% | -$444K-144.7% | $994K |
| Net loss before income taxes | -$6.3M+2.7% | -$6.5M+45.3% | -$11.8M-12.2% | -$10.5M-90.2% | -$5.5M |
| Net loss from continuing operations | -$6.3M+2.7% | -$6.5M+45.3% | -$11.8M | — | — |
| Loss from operations of discontinued component | -$2.6M-55.1% | -$1.7M+33.4% | -$2.6M | — | — |
| Loss on disposal of discontinued operations | -$100K+91.9% | -$1.2M+68.5% | -$3.9M | — | — |
| Net loss from discontinued operations | -$2.7M+6.6% | -$2.9M+54.6% | -$6.5M | — | — |
| Net loss | -$9.0M+4.0% | -$9.4M+48.6% | -$18.3M-73.7% | -$10.5M-90.2% | -$5.5M |
| Preferred dividends | -$1.3M-862.3% | -$130K | — | — | — |
| Net loss available to common stockholders | -$10.3M-7.8% | -$9.5M | — | — | — |
| Net loss per share from continuing operations basic | -$4.01+31.1% | -$5.82+53.6% | -$12.55 | — | — |
| Net loss per share from continuing operations diluted | -$4.01+31.1% | -$5.82+53.6% | -$12.55 | — | — |
| Loss per share from discontinued operations - Basic | -$1.75+34.0% | -$2.65+61.5% | -$6.88 | — | — |
| Loss per share from discontinued operations - diluted | -$1.75+34.0% | -$2.65+61.5% | -$6.88 | — | — |
| Net loss per share basic | -$5.76+32.0% | -$8.47+56.4% | -$19.43-4034.0% | -$0.47 | — |
| Net loss per share diluted | -$5.76+32.0% | -$8.47+56.4% | -$19.43 | — | — |
| Weighted average common shares outstanding, basic | 1.6M+41.2% | 1.1M+18.0% | 942K-95.8% | 22.6M | — |
| Weighted average common shares outstanding, diluted | 1.6M+41.2% | 1.1M+18.0% | 942K | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.